Vesalio's New Clinical Study for pVasc™ Thrombectomy System
Vesalio is embarking on an exciting clinical study initiative designed to gather real-world data for their groundbreaking pVasc™ Thrombectomy System. This comprehensive study aims to redefine treatment options for patients grappling with peripheral vascular disease and improve clinical outcomes significantly.
The pVasc™ Thrombectomy System: A Game-Changer
Vesalio, a pioneering company in thrombectomy solutions, is thrilled to announce the kick-off of a prospective, single-arm, multi-center clinical study. This study will focus on the pVasc™ Thrombectomy System, which has been specifically engineered for the effective non-surgical extraction of peripheral occlusions. By gathering valuable insights into the system's performance, the research objective is to better serve patients suffering from conditions like peripheral arterial occlusions (PAD), which can escalate to acute limb ischemia (ALI).
Challenges Faced by Current Thrombectomy Tools
In today's medical landscape, many thrombectomy devices face serious challenges. These complications often include difficulties in accessing smaller blood vessels, extended time needed for restoring blood flow, and the associated risk of distal embolization. The pVasc™ system is designed to tackle these hurdles with its innovative Drop Zone™ technology and a low-profile design, providing a refreshing solution to these persistent problems.
Upcoming Conferences: TCT, VIVA, and VEITH
As part of its commitment to advancing vascular care, Vesalio will participate in several prominent conferences in the near future. These include the TCT Conference, VIVA, and the VEITH Symposium, where leading experts will gather to discuss the potential of the pVasc™ Thrombectomy System and the accompanying data collection plan. Such interactions at these medical conferences are invaluable for fostering collaborations aimed at improving treatment methodologies and patient care.
CEO Insights on Advancements in Patient Care
"The launch of the pVasc™ system in the U.S. marks a pivotal moment in our mission to enhance patient outcomes for those affected by vascular occlusions," expressed Steve Rybka, CEO of Vesalio. He emphasized the importance of post-market data collection, asserting that it will validate the effectiveness of their technology while providing crucial support to physicians and improving patient results.
About Vesalio: A Commitment to Innovation
Founded in 2017, Vesalio is dedicated to revolutionizing the treatment of vascular diseases. The company strives to provide healthcare professionals with cutting-edge technologies that foster improved clinical outcomes. With its proprietary platforms, including NeVa™, enVast™, and pVasc™, Vesalio has successfully treated over 12,000 patients across more than 50 countries. The company’s mission is to continue enhancing vascular care through innovation and commitment.
Frequently Asked Questions
What is the primary goal of the clinical study for pVasc?
The study aims to collect real-world data to enhance treatment methods and optimize outcomes for patients suffering from peripheral vascular disease.
What challenges does the pVasc system aim to address?
The pVasc system is designed to overcome difficulties in accessing small arteries, restore blood flow efficiently, and minimize the risk of embolization.
Which conferences will Vesalio be attending?
Vesalio will be attending the TCT Conference, VIVA, and the VEITH Symposium to engage with leading vascular experts.
What products does Vesalio offer?
Vesalio offers several platforms including NeVa™, enVast™, and pVasc™, all aimed at improving treatment for various types of vascular diseases.
When was Vesalio founded?
Vesalio was established in 2017 and has since focused on developing advanced medical devices for better patient care.
